ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

EVO vs NGNE // 10Y YIELD & FRED MACRO BETA

Evotec SE (NASDAQ) VS. Neurogene Inc. (NASDAQ) • 15-METRIC TALLY: EVO 0 — NGNE 2
■ METRIC PARITY
macro-sensitivity
—
macro-sensitivity
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (EVO VS. NGNE) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC EVO NGNE SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) — -35.00% — TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield — -13.59% — TIE /fcf-yield <GO>
Operating Margin — — — TIE /operating-margins <GO>
Net Profit Margin — — — TIE /net-margins <GO>
Revenue Growth (YoY) — — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 12.76 — TIE /balance-sheet <GO>
Piotroski F-Score Quality — 2/9 — TIE /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 47.2 51.0 -3.76 NGNE /rsi-technicals <GO>
10Y Yield & FRED Macro Beta ACTIVE — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $562.1M $576.7M -$14.6M NGNE /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR EVO REV NGNE REV EVO GROSS % NGNE GROSS % EVO FCF NGNE FCF
FY 2025 — $0 — — — -$78.4M
FY 2024 — $925.0K — — — -$71.4M
FY 2023 — $0 — — — -$51.4M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
EVO // BETA —
NGNE // BETA —